-
Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions
-
In this paper, Dhruva et al examine the types of studies that were involved in premarket approval (PMA) of cardiovascular devices by the FDA over a seven-year period.
-
The ventricular tachycardia ablation in coronary Heart Disease (VTACH) study tested the hypothesis that mapping and prophylactic catheter ablation of ventricular tachycardia prior to implantable cardioverter defibrillator (ICD) insertion in patients with hemodynamically stable ventricular tachycardia (VT) would improve clinical outcomes.
-
Coronary revascularization without cardiopul-monary bypass has become quite successful, in part because of the belief that off-pump coronary bypass procedures are safer than on-pump surgery.
-
Resistant hypertension, defined as a systolic blood pressure (BP) that remains above goal despite treatment with at least three complementary antihypertensive agents of different classes at maximally tolerated doses, has become an increasingly common diagnosis in recent years.
-
Beta-blockers have long been considered a cornerstone of therapy for patients with acute myocardial infarction (MI).
-
This was a retrospective cohort study from Quebec and Ontario, Canada, examining patients ≥ 65 years of age admitted to a hospital with a diagnosis of atrial fibrillation (AF) between 1998 and 2007.
-
Current guidelines recommend monotherapy with either beta-blockers or rate lowering calcium blockers for heart rate control in patients with permanent atrial fibrillation (AF).
-
Recent controversy has erupted concerning the use of prophylactic beta-blockers in patients with known or suspected coronary artery disease (CAD) undergoing non-cardiac surgery.
-
The early ECGs are the mainstay of predicting the culprit coronary artery in ST-segment elevation myocardial infarction (STEMI)